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Abstract
Low apoptosis in the normal rectal mucosa has been associated with colorectal adenomas in cross-
sectional studies. It is unknown whether apoptosis can predict the occurrence of new adenomas. We
evaluated whether apoptosis at baseline colonoscopy, as well as patient and adenoma characteristics,
could predict future occurrence of adenomas. Study subjects were participants in the Diet and Health
Study III, a cross-sectional study of adenoma risk factors between August 1998 and March 2000. At
baseline, subjects underwent colonoscopy and provided normal rectal mucosal biopsies to evaluate
apoptosis as well as information about diet and lifestyle. The present study includes 257 subjects
who returned for follow-up colonoscopy between 2000 and 2005. Apoptosis, number of adenomas,
size, and atypia at baseline colonoscopy were evaluated as predictors of new adenomas. Logistic
regression was used to calculate odds ratios (OR) and 95% confidence intervals (95% CI). At
baseline, low apoptosis was significantly associated with increased risk of adenomas (P = 0.0001).
Compared with those in the lowest tertile, subjects with high apoptosis were less likely to have an
adenoma at follow-up (crude OR, 0.25; 95% CI, 0.09–0.65; adjusted OR, 0.29; 95% CI, 0.08–1.06).
Having three or more adenomas at baseline was associated with increased risk of new adenomas
(crude OR, 2.46; 95% CI, 1.14–5.31; adjusted OR, 3.74; 95% CI, 1.01–13.83). This study suggests
that lower apoptosis is associated with increased risk of future adenoma development. If confirmed
in larger studies, apoptosis could potentially be used to identify patients at highest risk for developing
new adenomas.
Introduction
In the United States and other developed countries, colorectal cancer is a substantial cause of
morbidity and mortality. It is generally agreed that the majority of colon cancers arise from
benign adenomas. Whereas most adenomas remain benign, a small proportion of adenomas
undergo a multistep process that eventuates in cancer (1). Patients with adenomas are at risk
to develop new adenomas (2). For that reason, individuals with prior adenomas are encouraged
to undergo follow-up colonoscopy at an interval determined by the size and number of
adenomas at baseline (3).
The variable intervals for follow-up colonoscopy are based on studies that have attempted to
identify risk factors for the development of new adenomas (2,4–6). Factors that have been
considered include size, number, degree of atypia, family history of colorectal cancer, and
adenoma location.
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We have shown that a low level of apoptosis in the normal rectal mucosa was a strong predictor
of adenomas elsewhere in the colon in a cross-sectional study, the Diet and Health Study III
(DHS3; 7). Apoptosis, or programmed cell death, is an important mechanism for eliminating
older or genetically damaged cells (8). Neoplasms can arise when decreased apoptosis leads
to the accumulation of genetically aberrant cells (9–12). Thus, apoptosis may serve a protective
role in the colorectal mucosa by preventing the development of adenomas and colorectal cancer
(13–15). Observation of low apoptosis in the normal rectal mucosa supports the concept of a
field effect, namely, that characteristics of the mucosa provide a substrate for the development
of adenomas.
Whereas low levels of apoptosis are associated with concomitant adenomas, it is not known
whether apoptosis will predict the occurrence of new adenomas. In the present study, we
examined the colonoscopy findings of a subset of patients who had baseline apoptosis
measurements and presented for follow-up colonoscopy to determine whether the baseline
level of apoptosis and other risk factors would predict future occurrence of new adenomas.
Materials and Methods
Patient Population
We evaluated a subset of participants enrolled in the DHS3, a cross-sectional study of adenoma
risk factors, who returned for follow-up colonoscopy at University of North Carolina Hospitals
between 2000 and 2005 to determine whether baseline apoptosis would predict the
development of new adenomas. The features of the patients enrolled in the initial DHS3 study
have been published in detail elsewhere (16). In brief, the DHS3 study recruited patients who
underwent colonoscopy for various reasons at the University of North Carolina Hospitals in
Chapel Hill between August 1, 1998 and March 4, 2000. Eligible patients were 30 years of age
or older, proficient in the English language, and without colitis, familial polyposis, previous
colonic resection, previous colon cancer, or adenoma. In preparation for colonoscopy, patients
used Golytely or Fleets Phosphosoda for bowel cleansing. Only patients who had
colonoscopies achieving complete visualization of the colon were included in the study. At the
time of baseline colonoscopy, six rectal pinch biopsies from normal mucosa were also obtained
from patients to evaluate apoptosis and proliferation. Patients also completed a detailed
lifestyle and dietary questionnaire. In the initial DHS3 study (baseline), cases were defined as
patients with at least one adenoma at colonoscopy and controls were patients with no adenomas.
Five hundred four subjects enrolled in DHS3 provided biopsies.
Data Collection
The present study reviewed medical records at University of North Carolina Hospitals to
identify previous DHS3 participants who returned for follow-up colonoscopy. We searched
the University of North Carolina Hospitals computerized medical records system (WEBCIS)
and identified patients from the DHS3 study who returned to University of North Carolina
Hospitals for follow-up colonoscopy between January 2000 and July 1, 2005. Of the 504
patients initially enrolled in the DHS3 study, 275 returned for follow-up colonoscopy. We
excluded 18 patients from the study because of unsatisfactory preparation of the colon at
follow-up colonoscopy, leaving 257 men and women who returned for follow-up colonoscopy.
This population included both patients who had adenomas at baseline and who returned for
surveillance and patients who were free of adenomas at baseline but who returned for clinically
indicated colonoscopy.
For each patient with follow-up colonoscopy, one investigator (A.A.) recorded the number of
adenomas found and the characteristics of each adenoma including size, location, histologic
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type, and degree of atypia. An experienced gastroenterologist (R.S.S.) reviewed a 10% sample
of records to assess reliability. The reliability was 100%.
Measurement of Apoptosis
Baseline apoptosis data were available on 191 subjects. The methods for evaluating apoptosis
have previously been described for the DHS3 study (7). Briefly, each biopsy specimen was
sectioned into five sections spaced 50 μm apart to avoid double counting of crypts. Apoptosis
was assessed on H&E-stained sections of biopsies of normal rectal mucosa obtained at baseline
colonoscopy using standard morphologic criteria. Cells were considered apoptotic by the
presence of cell shrinkage, chromatin condensation, and nuclear fragmentation. Apoptosis was
confirmed on a subset of specimens in DHS3 by the terminal deoxyribonucleotidyl transferase–
mediated dUTP nick end labeling (TUNEL) method (17). For TUNEL, cells were considered
apoptotic if they had nuclear brown staining of condensed chromatin or pyknotic dots of
condensed chromatin. Cells were not scored as apoptotic if the nucleus did not meet these
criteria. There was a positive correlation between the two apoptosis methods (Spearman
correlation coefficient = 0.73, P = 0.01). Using well-defined criteria for identifying scorable
crypts and apoptotic cells, an experienced technician who was blinded to adenoma status scored
all sections. A sample of slides was resubmitted for scoring in a blinded fashion to the same
scorer as well as an independent scorer to evaluate reproducibility. The level of agreement for
intra-rater scoring was 99% whereas inter-reader scoring reproducibility was 94%. The number
of apoptotic cells for each crypt was combined to calculate a mean apoptosis score per crypt.
A total of 8 to 12 longitudinal crypts were scored per biopsy on H&E- and TUNEL-stained
slides.
Data Analysis
Summary statistics were generated both overall and by case status in the form of means and
SEs for continuous variables or frequencies and percentages for categorical variables. Cases
and controls were compared via t tests for continuous variables and Fisher’s exact test for
categorical variables. Means and SEs of apoptosis were generated by categories for case
(adenoma versus no adenoma), age (under 45, 50–59, >60 years), race (self-reported race,
White, Black), sex (male/female), body mass index (BMI; normal, 18–24.9; overweight, 25–
29.9; obese, >30), nonsteroidal anti-inflammatory drug (NSAID) usage (<15 or >15 times/mo),
smoking (never, former, current), and family history of colorectal cancer (no/yes), and those
categories were compared by t tests and ANOVA. Tertile cutoff points for apoptosis were also
generated using the original DHS3 apoptosis data in controls. Logistic regression models were
used to examine the association between occurrence of new adenomas and baseline
demographic/lifestyle characteristics. Logistic regression was conducted among those with
adenomas at baseline only to examine the relationship between characteristic of baseline
adenoma and whether or not a subject had new adenomas at follow-up. The location of adenoma
was classified as proximal (cecum, ascending colon, hepatic flexure, and transverse colon) or
distal (splenic flexure, descending colon, sigmoid, rectosigmoid, and rectum). Both unadjusted
and adjusted models were run. For adjusted models, all covariables of interest were entered
into the model.
Results
The baseline characteristics at of DHS3 participants who returned for follow-up are presented
in Table 1. The number of subjects with baseline adenomas (case) who returned for follow-up
(n = 129) was similar to those without baseline adenomas (control) who returned for follow-
up (n = 128). Of the patients who had an adenoma at baseline colonoscopy, 41% had at least
one new adenoma at follow-up. In contrast, only 15% of individuals who were free of adenoma
at baseline had at least one new adenoma at follow-up. Among subjects who returned for
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follow-up colonoscopy (48.4%), the mean age was 58.4 years, 48% were males, and 28% had
a family history of colorectal cancer. Among those that did not return for follow-up, the mean
age was 54.6 years, 38% were males, and 22% reported a family history of colorectal cancer.
There were no significant differences in the baseline demographic characteristics of subjects
who did or did not return for follow-up (data not shown).
We examined whether the time interval from initial colonoscopy was related to adenoma status
at follow-up. Overall, those that had an adenoma at baseline had a shorter time to follow-up.
Among individuals that had adenomas at baseline, the time to follow-up was longer for
participants that had new adenomas at follow-up compared with those that did not (1,389 versus
1,253 days), but the results were not statistically significant. Among controls without adenomas
at baseline, there was no statistically significant difference in the time to follow-up for those
that had new adenoma at follow-up compared with those that did not (1,611–1,516 days).
Table 2 presents mean (SE) apoptosis scores by patient characteristics at baseline. The mean
apoptosis score was significantly lower in subjects with adenoma compared with those with
no adenoma at baseline. The mean apoptosis score was lower in males than in females but there
was no significant difference for any of the other patient characteristics.
We examined whether apoptosis and other risk factors such as baseline adenoma status, age,
and NSAID usage predicted the risk of future adenomas among subjects who returned for
follow-up colonoscopy (Table 3 ). Compared with subjects without adenomas at baseline, those
with adenomas at baseline were at significantly increased risk of having new adenomas at
follow-up [odds ratio (OR), 2.95; 95% confidence interval (95% CI), 1.19–7.33]. NSAID use
significantly predicted reduced risk of new adenoma occurrence. The results for apoptosis were
borderline significant (crude OR, 0.25; 95% CI, 0.09–0.65; adjusted OR, 0.29; 95% CI, 0.08–
1.06) after adjustment for age, race, sex, BMI, baseline case control status, and other variables
listed in the footnote for Table 1.
Among individuals with adenomas at baseline colonoscopy, certain characteristics of baseline
adenomas were associated with development of future adenomas (Table 4 ). The number of
adenomas at baseline positively predicted the occurrence of new adenomas (adjusted OR, 1.67;
95% CI, 1.11, 2.52). Compared with those with one or two adenomas, having three or more
adenomas at baseline was associated with the likelihood of developing new adenomas at
follow-up (adjusted OR, 3.74; 95% CI, 1.01–13.83). There was no statistically significant
association between the occurrence of new adenomas and presence of advanced adenoma at
baseline or baseline adenoma location. Forty-eight percent (48%) of patients with proximal
adenomas (cecum, ascending colon, hepatic flexure, transverse colon) at baseline had
occurrence of new lesions compared with 34% of those with distal baseline adenomas (splenic
flexure, descending colon, sigmoid rectosigmoid, and rectum), but this difference was not
statistically significant.
Discussion
The present study evaluated level of apoptosis as a predictor of occurrence of new adenomas
among subjects who underwent an initial baseline colonoscopy and returned for follow-up. We
also explored baseline patient and adenoma characteristics in relation to new adenoma
development. We observed an inverse association between apoptosis in the normal rectal
mucosa and occurrence of new adenomas. Subjects in the highest tertile of apoptosis were less
likely to have adenoma recurrence. Previously, we have shown in this population that low
apoptosis predicted increased risk of adenomas in a cross-sectional study (7,16). Thus, the
findings from the current prospective analysis support our previous observations and show that
apoptosis may be a valuable risk biomarker.
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Studies in animal models and humans also implicate deregulation of apoptosis in the neoplastic
process (18–21). Low levels of apoptosis in the colonic epithelium may provide the fertile
ground that allows for the unchecked growth of aberrant cells in the colon (7,15). Studies have
shown that individuals who lack an adenoma at baseline are unlikely to develop another
adenoma soon afterwards, and the recommended follow-up interval for colonoscopy is
prolonged for these patients (3). However, there is still a risk for future development of new
adenomas even among those that are free of adenoma at baseline. The present study suggests
that apoptosis in the normal rectal mucosa may identify those patients who may be at higher
risk and who would benefit from earlier follow-up colonoscopy. Unfortunately, the techniques
for apoptosis measurement are currently too tedious to be of clinical utility. If the measurement
could be automated, analysis of apoptosis in the rectal biopsies could serve as a risk biomarker
to determine the interval for the next colonoscopy. Larger longitudinal studies are needed to
confirm these findings. In addition, apoptosis in the normal rectal mucosa could serve as one
of a panel of potential biomarkers to evaluate effectiveness of a chemopreventive agent. If the
agent had a beneficial effect for apoptosis, it might be evaluated using other end points. Reports
from chemopreventive studies of colorectal cancer support the potential utility of apoptosis as
a biomarker. One study assessed the efficacy of celecoxib in familial adenomatous polyposis
patients and observed that increased apoptosis was significantly associated with polyp
regression and high apoptosis significantly correlated with better response to celecoxib (22).
Others have also reported similar findings (14,23–25). Because we have shown that levels of
apoptosis at baseline predict future adenomas, an intervention that raised apoptosis at baseline
could be a good candidate agent for adenoma prevention.
The present study showed that baseline NSAID use was strongly associated with reduced risk
of developing new adenomas. This observation is consistent with reports from other studies
(26,27). Aspirin and NSAIDs have been associated with reduced risk of colorectal adenomas
(7,28,29). A proposed mechanism for the chemoprotective effect of aspirin and NSAIDs is
through inhibition of prostaglandin synthesis. Although induction of apoptosis has also been
proposed as a mechanism for the protective effect of NSAIDs on colorectal adenomas and
cancer (30,31), we found that the association between adenomas and NSAIDs in average-risk
individuals was independent of apoptosis (7).
Certain risk factors, such as presence of adenomas at baseline, and characteristics of adenomas,
such as size and number of adenomas, may predict the development of new adenomas (2,4–
6,32). We found that the number of adenomas at baseline colonoscopy was associated with
elevated risk of new adenoma occurrence. Our results are compatible with prior reports in the
literature (2,5). However, adenoma size and location were not significant predictors of new
adenoma occurrence, possibly due to small sample size. Previous studies have shown
inconsistent results for the association between these two variables and occurrence of new
adenomas (2–5).
Our study makes a unique contribution to the literature by suggesting apoptosis as a predictor
of occurrence of new adenomas. Additional advantages of this study are inclusion only of
patients with adequate prep and complete visualization of the colon to the cecum at baseline
and follow-up colonoscopy. We minimized inter- and intra-observer bias by having the same
pathologist to evaluate all pathologic lesions at baseline and follow-up using predefined
criteria. We also had one technician to evaluate apoptosis in the study. Limitations of this study
include small sample size and incomplete follow-up. Because not all subjects in the initial study
returned for follow-up, our study may be biased. However, the baseline demographic
characteristics of those who returned for follow-up were similar to those who did not return
for follow-up. Likewise, the proportions of subjects with and without adenomas at baseline
who returned for follow-up were comparable.
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In summary, our study provides new evidence that lower levels of apoptosis at baseline are
associated with the risk of developing new adenomas. Apoptosis could potentially be used to
identify patients at highest risk for development of future adenomas especially among those
who are free of adenomas during an initial colonoscopy.
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Table 1
Baseline characteristics of DHS3 study participants who returned for follow-up
Overall (n = 257)*
Characteristic
Baseline case/control status
Adenoma, n (%) 129 (50)
No adenoma, n (%) 128 (50)
Mean age (SE), y 58.4 (0.7)
Race
 White, n (%) 198 (80)
 Black, n (%) 51 (20)
Sex
 Male, n (%) 123 (48)
 Female, n (%) 134 (52)
BMI (kg/m2)
 Normal (18–24.9), n (%) 92 (36)
 Overweight (25–29.9), n (%) 82(32)
 Obese (>30), n (%) 80 (32)
Mean NSAID use/mo (SE) 8.1 (0.8)




Family history of colorectal cancer, n (%) 69 (28)
 Yes 69 (28)
 No 178 (72)
Mean daily calories (SE), kcal 1,525 (36)
Mean apoptosis (SE) 2.70 (0.05)
•
All subjects who returned for follow-up colonoscopy.
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Table 2
Apoptosis and baseline patient characteristics
Variable Mean apoptosis (SE) P*
Case status
 Adenoma 2.43 (0.06) 0.0001
 No adenoma 3.00 (0.06)
Age (y)




 White 2.72 (0.06) 0.71
 Black 2.68 (0.10)
Sex
 Male 2.59 (0.07) 0.03
 Female 2.79 (0.06)
BMI (kg/m2)
 Normal (18–24.9) 2.78 (0.08) 0.10
 Overweight (25–29.9) 2.55 (0.08)
 Obese (>30) 2.74 (0.08)
NSAIDs used >15 times/mo
 No 2.74 (0.06) 0.18
 Yes 2.58 (0.10)
Smoking status
 Never 2.71 (0.07) 0.60
 Former 2.66 (0.08)
 Current 2.81 (0.12)
Family history of colorectal cancer†
 No 2.68 (0.06) 0.38
 Yes 2.78 (0.10)
*
P values were generated via ANOVA.
†
Family history of colorectal cancer includes first-degree relatives.
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Table 3
Baseline characteristics and occurrence of new adenomas
Baseline measure Crude OR (95% CI) Adjusted OR* (95% CI)
Case status
 No adenoma 1.0 (reference) 1.0 (reference)
 Adenoma 4.00 (2.19–7.29) 2.95 (1.19–7.33)
Age (5-y increment) 1.10 (0.96–1.25) 1.08 (0.87–1.34)
Race
 White 1.0 (reference) 1.0 (reference)
 Black 0.74 (0.36–1.52) 0.39 (0.14–1.03)
Sex
 Female 1.0 (reference) 1.0 (reference)
 Male 1.54 (0.89–2.66) 1.98 (0.82–4.74)
BMI (kg/m2)
 Normal (18–24.9) 1.0 (reference) 1.0 (reference)
 Overweight (25–29.9) 1.97 (1.01–3.85) 1.48 (0.56–3.94)
 Obese (>30) 1.45 (0.73–2.90) 1.74 (0.62–4.86)
Used NSAIDs >15 times/mo
 No 1.0 (reference) 1.0 (reference)
 Yes 0.58 (0.28–1.21) 0.28 (0.10–0.80)
Smoking
 Never 1.0 (reference) 1.0 (reference)
 Former 1.12 (0.62–2.04) 1.30 (0.54–3.13)
 Current 0.69 (0.28–1.66) 0.69 (0.19–2.59)
Family history of colorectal cancer, n (%)
 No 1.0 (reference) 1.0 (reference)
 Yes 0.97 (0.52–1.81) 0.70 (0.26–1.90)
Daily calories (increment of 100) 0.98 (0.93–1.03) 0.99 (0.91–1.06)
Apoptosis†
 Tertile 1 (1.29–2.46) 1.0 (reference) 1.0 (reference)
 Tertile 2 (2.48–3.00) 0.99 (0.48–2.01) 1.75 (0.70–4.41)
 Tertile 3 (3.04–6.90) 0.25 (0.09–0.65) 0.29 (0.08–1.06)
*
OR adjusted for age, race, sex, BMI, NSAIDs, smoking, family history of colorectal cancer, calories, apoptosis, bowel prep, and baseline case/control
status.
†
Apoptosis data were available for 102 cases and 89 controls (the number of patients in apoptosis tertiles was for tertile 1, case/control = 61/18; tertile 2,
case/control = 29/30; tertile 3, case/control = 27/39; 27 cases were missing and 39 controls were missing).
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Table 4
Baseline adenoma characteristics and occurrence of new adenomas
Crude OR (95% CI) Adjusted OR* (95% CI)
Indication for earlier endoscopy†
 No 1.0 (reference) 1.0 (reference)
 Yes 2.39 (1.17–4.92) 2.03 (0.69–6.00)
Advanced adenoma at baseline
 No 1.0 (reference) 1.0 (reference)
 Yes 1.61 (0.77–3.38) 1.09 (0.32–3.70)
No. adenomas at baseline
 1–2 1.0 (reference) 1.0 (reference)
 ≥3 2.46 (1.14–5.31) 3.74 (1.01–13.83)
Location‡
 Distal 1.0 (reference) 1.0 (reference)
 Proximal 1.78 (0.72–4.41) 3.95 (0.85–18.33)
 >1 2.79 (1.06–7.31) 1.54 (0.37–6.39)
*
OR adjusted for age, race, sex, BMI, NSAIDs, smoking, family history of colorectal cancer, calories, apoptosis, bowel prep, and baseline adenoma status.
†
Indication for earlier endoscopy was defined as having adenoma at least 1 cm in diameter or villous histology or severe atypia or (43 patients), 3 or more
adenomas (21 patients). Advanced adenoma was defined as having an adenoma at least 1 cm in diameter, histology of villoglandular or villous or severe
atypia.
‡
Adenoma distal location included splenic flexure, descending colon, sigmoid, rectosigmoid, and rectum. Proximal location included cecum, ascending
colon, hepatic flexure, and transverse colon.
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